MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    PDQ-39 predicts quality of life improvement following neurostimulation for Parkinson’s disease: Prospective observational study

    L. Torrão, M. Rosas, J. Massano, A. Oliveira, C. Chamadoira, M. Rito, J. Guimarães, C. Soares (Póvoa de Varzim, Portugal)

    Objective: The primary outcome was assessing QoL of a cohort of patients with PD before and after undergoing DBS surgery, measured using PDQ-39 questionary. Secondary…
  • 2023 International Congress

    Artificial intelligence for the improvement of imaging biomarkers in Parkinson’s disease

    V. Dzialas, E. Doering, K. Simonyan, A. Strafella, D. Vaillancourt, T. van Eimeren (Cologne, Germany)

    Objective: To systematically review the current literature on the application of artificial intelligence (AI) for imaging biomarkers in Parkinson's disease (PD) and to identify translational…
  • 2023 International Congress

    Evaluation of structural brain stem measurements for the differential diagnosis of MSA and IPD

    M. Loffeld, S. Kannenberg, A. Hausmann, C. Hartmann, J. Caspers, C. Rubbert, A. Schnitzler (Düsseldorf, Germany)

    Objective: To evaluate structural brain stem measurements to differentiate multiple system atrophy (MSA) from idiopathic Parkinson‘s disease (IPD). Background: MSA is a sporadic, progressive, neurodegenerative…
  • 2023 International Congress

    Applying the COM-B model to identify potential barriers for in-person on-site visits within the Healthy Brain Ageing (HeBA) study in Luxembourg

    L. Vilas Boas, O. Tsurkalenko, T. Marques, E. Thiry, AM. Hanff, R. Krüger, C. Horlings, A. Garrido, C. Vega, S. Schade, P. Mahlknecht, C. Gomes, S. Ghosh, K. Rege, R. Rawal, C. Pauly, D. Mcintyre, K. Seppi, M. Martí, C. Trenkwalder, E. Tolosa, W. Poewe, V. Satagopam, B. Mollenhauer (Strassen, Luxembourg)

    Objective: This study aims to (1) apply the Capability, Opportunity, and Motivation model of Behaviour (COM-B) to the HeBA online survey to identify potential barriers that could…
  • 2023 International Congress

    Subjective cognitive decline as predictor of objective cognitive decline in Parkinson’s patients

    T. Blum, H. Wurp, S. Wolfsgruber, M. Wagner, L. Consortium, R. Dodel (Essen, Germany)

    Objective: The present study cross-sectionally and longitudinally explores the predictive value of subjective cognitive decline (SCD) regarding objective cognitive decline in a large clinical sample…
  • 2023 International Congress

    Assessing the optimal pallidal target in deep brain stimulation for Parkinson’s disease: A single-center retrospective review

    D. Schumacher, D. Paulo, D. Doss, S. Narasimhan, L. Rui, D. Benoit, D. Englot, A. Giritharan (Nashville, USA)

    Objective: To characterize globus pallidus internus (GPi) deep brain stimulation (DBS) active contact location at one-year post-op for Parkinson’s disease (PD) patients at our center.…
  • 2023 International Congress

    Impaired structural connectivity in Parkinson’s disease with probable RBD

    J. Oltra, I. Roura, A. Campabadal, C. Uribe, J. Pardo, MJ. Martí, Y. Compta, F. Valldeoriola, N. Bargallo, A. Iranzo, C. Junque, B. Segura (Barcelona, Spain)

    Objective: To characterize structural connectivity through whole-brain network-based statistics and graph theory implementation in treated Parkinson’s disease (PD) patients with probable REM sleep behavior disorder…
  • 2023 International Congress

    Randomized Controlled Trial comparing continuous intrajejunal levodopa infusion and deep brain stimulation for Parkinson’s disease. Cost-effectiveness and cost-utility outcomes of the INVEST study

    D. van Poppelen, M. van Barreveld, R. de Bie, P. Schuurman, F. van Delft, G. Geurtsen, R. de Haan, M. Dijkgraaf, J. Dijk (Amsterdam, Netherlands)

    Objective: To determine the costs of continuous intrajejunal levodopa infusion (CILI) and deep brain stimulation (DBS) for Parkinson’s disease (PD), and to study the cost-effectiveness…
  • 2023 International Congress

    Individual-specific brain functional connectivity mapping of therapeutic response in task-specific focal dystonia

    E. Gordon, K. Matthews, A. Meyer, S. Norris (St. Louis, USA)

    Objective: Determine therapeutic effects of botulinum toxin on functional connectivity in individuals with task-specific dystonia. Background: Isolated task-specific dystonia occurs during specific activities, but not…
  • 2023 International Congress

    Basal ganglia shape in de novo Parkinson’s disease patients can predict the onset of Levodopa Induced Dyskinesias

    S. Shukla, M. Patnaik, A. Kumar, N. Thirugnanasambandam, S. Tinaz (Mumbai, India)

    Objective: In the current study, we aimed to examine structural MRI data from a large sample of de novo PD patients and to identify potential…
  • « Previous Page
  • 1
  • …
  • 107
  • 108
  • 109
  • 110
  • 111
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24187 (not found)
  • #29526 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • “Striatal Hand Signs” and early diagnosis of Parkinson's Disease: The “Monkey-Wrench Sign”.
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley